• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Phase I (first-in-man) prophylactic vaccine's clinical trials: Selecting a clinical trial site.I期(首次人体)预防性疫苗临床试验:选择临床试验地点。
Perspect Clin Res. 2015 Apr-Jun;6(2):77-81. doi: 10.4103/2229-3485.154001.
2
HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen.HIV gp120疫苗 - 瓦克斯根公司:AIDSVAX、AIDSVAX B/B、AIDSVAX B/E、HIV gp120疫苗 - 基因泰克公司、HIV gp120疫苗AIDSVAX - 瓦克斯根公司、HIV疫苗AIDSVAX - 瓦克斯根公司
Drugs R D. 2003;4(4):249-53. doi: 10.2165/00126839-200304040-00007.
3
Enrolling study personnel in Ebola vaccine trials: from guidelines to practice in a non-epidemic context.招募研究人员参与埃博拉疫苗试验:从指南到非流行环境下的实践。
Trials. 2019 Jul 11;20(1):422. doi: 10.1186/s13063-019-3487-0.
4
Staphylococcus aureus vaccine conjugate--Nabi: Nabi-StaphVAX, StaphVAX.金黄色葡萄球菌疫苗偶联物——纳比公司:纳比-葡萄球菌疫苗、葡萄球菌疫苗
Drugs R D. 2003;4(6):383-5. doi: 10.2165/00126839-200304060-00013.
5
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
6
VACCELERATE Site Network: Real-time definition of clinical study capacity in Europe.VACCELERATE 站点网络:欧洲临床研究能力的实时定义。
Vaccine. 2023 Jun 13;41(26):3915-3922. doi: 10.1016/j.vaccine.2023.05.006. Epub 2023 May 18.
7
Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.流感病毒减毒活疫苗鼻内接种——MedImmune疫苗:CAIV-T,流感病毒减毒活疫苗鼻内接种。
Drugs R D. 2003;4(5):312-9. doi: 10.2165/00126839-200304050-00007.
8
Trauma intensive care unit (TICU) at Hamad General Hospital.哈马德总医院创伤重症监护病房(TICU)。
Qatar Med J. 2020 Feb 6;2019(2):5. doi: 10.5339/qmj.2019.qccc.5. eCollection 2019.
9
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
10
Assessment of Communication Strategies for Mitigating COVID-19 Vaccine-Specific Hesitancy in Canada.评估加拿大减轻 COVID-19 疫苗犹豫相关沟通策略。
JAMA Netw Open. 2021 Sep 1;4(9):e2126635. doi: 10.1001/jamanetworkopen.2021.26635.

引用本文的文献

1
Discovering vaccines: the trial tale.发现疫苗:试验故事
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jan;398(1):363-377. doi: 10.1007/s00210-024-03368-1. Epub 2024 Aug 23.
2
Site readiness practices for clinical trials - considerations for CTSA hubs.临床试验的场地准备工作——CTSA中心的考量因素
J Clin Transl Sci. 2023 Jun 29;7(1):e146. doi: 10.1017/cts.2023.569. eCollection 2023.

本文引用的文献

1
Guidelines on similar biologics: regulatory requirements for marketing authorization in India.类似生物制品指南:印度上市许可的监管要求
PDA J Pharm Sci Technol. 2012 Sep-Oct;66(5):393. doi: 10.5731/pdajpst.2012.00886.
2
International Conference on Harmonisation; Guidance on M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals; availability. Notice.国际协调会议;关于药品进行人体临床试验和上市许可的M3(R2)非临床安全性研究的指南;可获取性。通知。
Fed Regist. 2010 Jan 21;75(13):3471-2.
3
Preclinical safety evaluation of biotechnology-derived pharmaceuticals.生物技术衍生药物的临床前安全性评估。
Nat Rev Drug Discov. 2002 Jun;1(6):469-75. doi: 10.1038/nrd822.

I期(首次人体)预防性疫苗临床试验:选择临床试验地点。

Phase I (first-in-man) prophylactic vaccine's clinical trials: Selecting a clinical trial site.

作者信息

Mehta Shantanu, Goyal Vishal, Singh Kavita

机构信息

Clinical Development, Malaria Vaccine Development Program, International Centre for Genetic Engineering and Biotechnology Campus, New Delhi, India.

出版信息

Perspect Clin Res. 2015 Apr-Jun;6(2):77-81. doi: 10.4103/2229-3485.154001.

DOI:10.4103/2229-3485.154001
PMID:25878951
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4394584/
Abstract

An appropriately equipped and staffed Phase I unit is critical for smooth conduct of a first-in-man clinical trial. The first-in-man prophylactic vaccine trial(s) requires basic infrastructure of clinical trial site, experienced and dedicated site staff and healthy adults as volunteers. The facility should have access to equipment, emergency services, laboratory, pharmacy and archiving. In terms of design, infrastructure, workflow and manpower, a Phase I unit for testing a novel vaccine or drug are quite similar. However, there are some important attributes, which should be taken into consideration, while performing pre-trial site selection for conducting phase I trial with a new or novel vaccine.

摘要

配备适当设备和人员的一期临床试验单元对于首次人体临床试验的顺利开展至关重要。首次人体预防性疫苗试验需要临床试验场所的基本基础设施、经验丰富且专注的场所工作人员以及健康成年人作为志愿者。该设施应配备设备、提供应急服务、设有实验室、药房和存档处。在设计、基础设施、工作流程和人力方面,用于测试新型疫苗或药物的一期临床试验单元颇为相似。然而,在用新的或新型疫苗进行一期临床试验的试验前场所选择过程中,有一些重要因素需要考虑。